The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis (Q45016242)
scientific article
Language:
(P31) (Q13442814)
(P50) (Q43187559)
(Q26338766)
(Q114439788)
(P304) 2247-2256
(P407) (Q1860)
(P433) 12
(P478) 22
(P577) Thursday, September 4, 2008
(P921) (Q203174)
(Q422252)
(P1433) (Q6534498)
(P1476) "The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis" (language: en)
(P2093) E Terpos
M Roussou
D Heath
D Christoulas
N Anagnostopoulos
K Tsionos
P Croucher
(P2507) (Q57904750)
(P2860) (Q36062445)
(Q45876706)
(Q36889961)
(Q44189620)
(Q53539699)
(Q44211035)
(Q46985882)
(Q46898065)
(Q60203808)
(Q44817129)
(Q46634193)
(Q57904843)
(Q36870585)
(Q44746790)
(Q46882677)
(Q34549410)
(Q57904871)
(Q79084045)
(Q57904812)
(Q46410865)
(Q79407795)
(Q53259579)
(Q44498887)
(Q33348702)
(Q44032751)
(Q80557114)
(Q79766223)
(Q46570802)
(Q51538830)
(Q52925512)
(Q79984687)
(Q36616740)
(Q36818075)
(Q46812650)
(Q46946161)
(Q51067506)
(Q80146976)
other details
description scientific article

External Links